Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.

Diabetes Obes Metab · 2019 · PMC6585815 · PMID 30136354

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

While a mild and marginally significant decline in eGFR was observed during dapagliflozin use, there was no evidence of clinically meaningful impairment in renal function.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.